Regarding the male patients, there are other publications concentrated on this matter describing tumors in men [42] that give an excellent description, concluding that “surveillance programs in men with BRCA1 and BRCA2 pathogenic variants should be tailored in light of these gene-specific cancer phenotype differences. The gene discussed is BRCA2; the disease is cancer.